ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger<\/strong> (Department of Urology, University of Lubeck, Germany), touchONCOLOGY’s Editor-in-Chief, joins us to share his highlights.<\/p>\n
In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy in patients with prostate cancer (0:40); the interim overall survival results in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (1:33); a study investigating ICE collaboration in clinical endpoints in rPFS and cPFS that appear to be valid surrogate endpoints for OS in prostate cancer (2:00); the first results of the phase 3 MAGNITUDE trial, and PROPEL trial (2:39), phase 2 lutetium 177 trial, and phase 3 VISION trial, targeted radioligand therapy with lutetium 177 vipivotide tetraxetan (3:20). Finally, he discusses a study around SUV mean that was shown to be strongly associated with overall survival in PSMA imaging in prostate cancer (4:41).<\/p>\n
ASCO 2022 Abstracts discussed in this interview:<\/strong><\/p>\n
Abstract #5001: Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial<\/a><\/p>\n<\/div>\n<\/li>\n<\/ol>\n
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO<\/a>) annual meeting.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"